NZ545459A - Quinazoline analogs as receptor tyrosine kinase inhibitors - Google Patents
Quinazoline analogs as receptor tyrosine kinase inhibitorsInfo
- Publication number
- NZ545459A NZ545459A NZ545459A NZ54545904A NZ545459A NZ 545459 A NZ545459 A NZ 545459A NZ 545459 A NZ545459 A NZ 545459A NZ 54545904 A NZ54545904 A NZ 54545904A NZ 545459 A NZ545459 A NZ 545459A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- cycloalkyl
- heterocyclyl
- nmr
- mhz
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Structural Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/642,440 US7501427B2 (en) | 2003-08-14 | 2003-08-14 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
US55171804P | 2004-03-10 | 2004-03-10 | |
PCT/US2004/026235 WO2005016346A1 (en) | 2003-08-14 | 2004-08-10 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ545459A true NZ545459A (en) | 2009-12-24 |
Family
ID=34198338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ545459A NZ545459A (en) | 2003-08-14 | 2004-08-10 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Country Status (24)
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
PT1971601E (pt) | 2005-11-15 | 2010-01-26 | Array Biopharma Inc | Derivados de n4-fenil-quinazolina-4-amina e compostos relacionados como inibidores de tirosina quinases receptoras do tipo i erbb para o tratamento de doenças hiperproliferativas |
MX353970B (es) | 2011-10-14 | 2018-02-07 | Array Biopharma Inc | Dispersion solida. |
CN104011047A (zh) | 2011-10-14 | 2014-08-27 | 阵列生物制药公司 | 选择性herb2抑制剂arry-380的多晶型物和含有它们的药物组合物 |
PT3400943T (pt) | 2012-03-23 | 2021-02-02 | Array Biopharma Inc | Compostos para serem utilizados no tratamendo de metástase no cérebro num doente com cancro da mama positivo para erbb2. |
KR20180048804A (ko) * | 2015-09-04 | 2018-05-10 | 아슬란 파마슈티컬스 피티이 엘티디 | 바리티닙 및 항암제를 포함하는 병용 요법 |
WO2017184086A1 (en) * | 2016-04-21 | 2017-10-26 | Aslan Pharmaceuticals Pte. Ltd. | Method of treating liver cancer |
GB201611580D0 (en) * | 2016-07-01 | 2016-08-17 | Aslan Pharmaceuticals Pte Ltd | Method |
CN106349231A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂 |
CN106279135A (zh) * | 2016-08-09 | 2017-01-04 | 浙江医药高等专科学校 | 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂 |
CN106349230A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
CN106317040A (zh) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途 |
CN106317039A (zh) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途 |
SG10201913858WA (en) | 2016-08-26 | 2020-03-30 | Agency Science Tech & Res | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |
TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
US11207324B2 (en) | 2017-04-28 | 2021-12-28 | Seagen Inc. | Treatment of HER2 positive cancers |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
RS65413B1 (sr) | 2018-09-18 | 2024-05-31 | Hoffmann La Roche | Derivati hinazolina kao antitumorski agensi |
EP3864014B1 (en) | 2018-10-09 | 2023-07-05 | ASLAN Pharmaceuticals Pte Ltd | Malonate salt of varlitinib |
CN111499622B (zh) * | 2019-07-08 | 2023-06-06 | 山东省科学院菏泽分院 | 一种治疗胆管癌的药物的制备方法 |
TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Her2突變抑制劑 |
WO2023185793A1 (zh) * | 2022-03-28 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2583774A (en) * | 1948-04-30 | 1952-01-29 | Merck & Co Inc | Vitamin b6 derivatives |
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
US5204348A (en) | 1988-10-06 | 1993-04-20 | Mitsui Toatsu Chemicals Inc. | Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components |
CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (US07981874-20110719-C00313.png) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
SI0892789T2 (sl) * | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
DK0912559T3 (da) | 1996-07-13 | 2003-03-10 | Glaxo Group Ltd | Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
ID23978A (id) | 1997-11-11 | 2000-06-14 | Pfizer Prod Inc | Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker |
WO1999044612A1 (en) | 1998-03-02 | 1999-09-10 | Cocensys, Inc. | Substituted quinazolines and analogs and the use thereof |
US6017922A (en) * | 1998-05-18 | 2000-01-25 | U.S. Bioscience, Inc. | Thermally stable trimetrexates and processes for producing the same |
ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
NZ513433A (en) | 1999-01-13 | 2003-05-30 | Warner Lambert Co | Benzoheterocycles, their use as MEK inhibitors and use in treating proliferative diseases such as cancer |
DK1553097T3 (da) * | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
SK3832002A3 (en) | 1999-09-21 | 2002-11-06 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
CZ20022771A3 (cs) * | 2000-02-17 | 2003-09-17 | Bristol-Myers Squibb Company | Ligandy thyreoidního receptoru odvozené od anilinu |
MXPA02012034A (es) | 2000-06-06 | 2003-04-25 | Pfizer Prod Inc | Derivados de tiofeno utiles como agentes anticancerosos. |
NZ522568A (en) * | 2000-06-22 | 2004-12-24 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
CN1211382C (zh) * | 2000-06-30 | 2005-07-20 | 葛兰素集团有限公司 | 喹唑啉二甲苯磺酸盐化合物 |
US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2002361577A1 (en) | 2001-10-30 | 2003-05-12 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
DE60231230D1 (de) * | 2001-11-03 | 2009-04-02 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
AU2002353196B2 (en) * | 2001-12-24 | 2008-01-17 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
KR20050122199A (ko) | 2003-01-23 | 2005-12-28 | 티.케이. 시그널 리미티드 | 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도 |
PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
MXPA05012839A (es) * | 2003-05-27 | 2006-05-17 | Pfizer Prod Inc | Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa. |
KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
US7501427B2 (en) * | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
EP1658080A1 (en) | 2003-08-18 | 2006-05-24 | Pfizer Products Inc. | Dosing schedule for a erbb2 anticancer agents |
WO2005044302A1 (en) | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
PT1971601E (pt) | 2005-11-15 | 2010-01-26 | Array Biopharma Inc | Derivados de n4-fenil-quinazolina-4-amina e compostos relacionados como inibidores de tirosina quinases receptoras do tipo i erbb para o tratamento de doenças hiperproliferativas |
-
2004
- 2004-08-10 KR KR1020107000942A patent/KR101028952B1/ko active IP Right Grant
- 2004-08-10 KR KR1020067003060A patent/KR100953246B1/ko active IP Right Grant
- 2004-08-10 JP JP2006523384A patent/JP4828421B2/ja active Active
- 2004-08-10 MX MXPA06001767A patent/MXPA06001767A/es active IP Right Grant
- 2004-08-10 EP EP04780990A patent/EP1660090B1/en active Active
- 2004-08-10 WO PCT/US2004/026235 patent/WO2005016346A1/en active Application Filing
- 2004-08-10 PL PL04780990T patent/PL1660090T3/pl unknown
- 2004-08-10 BR BRPI0413565A patent/BRPI0413565B8/pt active IP Right Grant
- 2004-08-10 CA CA002535614A patent/CA2535614C/en active Active
- 2004-08-10 DK DK04780990.0T patent/DK1660090T3/da active
- 2004-08-10 CN CN201310428856.4A patent/CN103664802B/zh active Active
- 2004-08-10 US US10/914,974 patent/US7452895B2/en active Active
- 2004-08-10 ES ES04780990T patent/ES2399427T3/es active Active
- 2004-08-10 RU RU2006103493/04A patent/RU2350605C2/ru active
- 2004-08-10 CN CN201110283526.1A patent/CN102432552B/zh active Active
- 2004-08-10 CN CN201310581100.3A patent/CN103772373B/zh active Active
- 2004-08-10 PT PT47809900T patent/PT1660090E/pt unknown
- 2004-08-10 NZ NZ545459A patent/NZ545459A/en unknown
- 2004-08-10 AU AU2004264937A patent/AU2004264937B2/en active Active
- 2004-08-13 AR ARP040102929A patent/AR045378A1/es active IP Right Grant
- 2004-08-13 CL CL200402066A patent/CL2004002066A1/es unknown
- 2004-08-13 TW TW093124336A patent/TWI353982B/zh active
-
2006
- 2006-02-07 IS IS8288A patent/IS8288A/is unknown
- 2006-02-07 IL IL173593A patent/IL173593A/en active IP Right Grant
- 2006-03-13 NO NO20061171A patent/NO336275B1/no unknown
- 2006-06-05 HK HK06106407.8A patent/HK1085400A1/xx unknown
-
2008
- 2008-10-10 US US12/249,421 patent/US8278314B2/en active Active
-
2013
- 2013-02-08 CY CY20131100122T patent/CY1113992T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11174273B2 (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
US8278314B2 (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
US10780073B2 (en) | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
EP1877397B1 (en) | Quinazoline derivatives as inhibitors of egf and/or erbb2 receptor tyrosine kinase | |
EP1877398B1 (en) | Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors | |
EP1928861B1 (en) | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer | |
US20090239861A1 (en) | Quinazoline derivatives as anticancer agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 AUG 2017 BY COMPUTER PACKAGES INC Effective date: 20140828 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2018 BY COMPUTER PACKAGES INC Effective date: 20170718 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2019 BY COMPUTER PACKAGES INC Effective date: 20180718 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2020 BY COMPUTER PACKAGES INC Effective date: 20190718 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2021 BY THOMSON REUTERS Effective date: 20200721 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2022 BY THOMSON REUTERS Effective date: 20210702 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2023 BY THOMSON REUTERS Effective date: 20220704 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 AUG 2024 BY THOMSON REUTERS Effective date: 20230703 |